Does vancomycine increase aminoglycoside nephrotoxicity?

Pediatrics International

Volumn 39, Issue 4, 1997, Pages 422-427

  Ergür, AyÇa törel ^a   Onarlioglu, Bilge ^a   Günay, Yasemin ^a   Çetinkaya, öge ^a   Bulut, Hüseyin eray ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Amikacin; Nephrotoxicity; Vancomycine

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CREATININE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG POTENTIATION; GLOMERULUS; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY TUBULE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; UREA NITROGEN BLOOD LEVEL;

AMIKACIN; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; KIDNEY; RATS; RATS, WISTAR; VANCOMYCIN;

EID: 0030764935     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.1997.tb03610.x     Document Type: Article

References (19)

1. Appel BG. Aminoglycoside nephrotoxicity. Am. J. Med. 1990; 88 (Suppl. 3C): 16–24.
2. Sigenthaler WE, Bonetti A., Lughy R. Aminoglycoside antibiotics in infectious disease: An overview. Am. J. Med. 1986; 80 (Suppl. 6B): 2–14.
3. Moellering RC. Have the new Beta-lactams rendered the aminoglycosides obsolete for the treatment of serious nosocomial infections? Am. J. Med. 1986; 80 (Suppl. 6B): 44–7.
4. Appel GB, Neu HC. The nephrotoxicity of antimicrobial agents. N. Engl. J. Med. 1987; 296: 663–70.
5. Gouvea W., Vaamonde CM, Ovens B. et al. The protection against gentamicin nephrotoxicity in the streptozotocin-induced diabetic rat is not related to gender. Life Sci. 1992; 51: 1747–58.
6. Humes MD, Weinberg JM, Knaus TC. Clinical and psychophysiologic aspects of aminoglycoside antibiotics in infectious disease. Am. J. Kidney Dis. 1982; 2: 5–29.
7. Rasmussen MH, Ibels LS. Acute renal failure. Multivariate analysis of causes and risk factors. Am. J. Med. 1982; 73: 211–18.
8. Wold JJ, Turnipseed SA. Toxicology of vancomycine in laboratory animals. Rev. Infect. Dis. 1981; 3: S224–35.
9. Shusterman N., Strom BL, Murray TG et al. Risk factors and outcome of hospital-acquired acute renal failure. Am. J. Med. 1987; 83: 65–71.
10. Brier ME, Mayer PR, Brier RA. Relationship between rat renal accumulation of gentamicin, tobramicin and their nephrotoxicities. Antimicrob. Agents Chemother. 1988; 27: 812–16.
11. Silverblatt F. Pathogenesis of nephrotoxicity of cephalosporins and aminoglycosides: a review of current concepts. Rev. Infect. Dis. 1982; 4 (Suppl.): 360–5.
12. Tulkens PM. Experimental studies on nephrotoxicity of aminoglycosides at low doses. Am. J. Med. 1986; 80 (Suppl. 6B): 105–14.
13. Marshall PG, Baker JR, Shenep JL. Vancomycine does not enhance amikacin-induced tubular nephrotoxicity in children. Pediatr. Infect. Dis. 1989; 8: 278–82.
14. Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycine from 1974 to 1981. Antimicrob. Agents Chemother. 1983; 23: 138–41.
15. Sorrel TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycine therapy. J. Antimicrob. Chemother. 1985; 16: 235–41.
16. Cimino MA, Rotstein C., Slaughter RL et al. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycine therapy. Am. J. Med. 1987; 83: 1091–7.
17. Marre MR. Renal tolerance and pharmacokinetics of vancomycine in rats. J. Antimicrob. Chemother. 1984; 14: 253–60.
18. Appel GB, Given PB, Levine R. Vancomycine and the kidney. Am. J. Kidney Dis. 1986; 8: 75–80.
19. Loed S. Handbook of Pediatric Drug Therapy. Spring House Corporation, Pennsylvania. 1990.